Note: This document has been translated from the Japanese original for reference purpose only. In the event ofany discrepancy between this translated document and the Japanese original, the original shall prevail.

Consolidated Financial Results
for the Six Months Ended June 30, 2024
[Under Japanese GAAP]
August 13, 2024
Company name:

FINDEX Inc.
Listing:
Tokyo Stock Exchange
Securities code:
3649
URL:
https://findex.co.jp/en/index.html
Representative:
Teruo Aibara, President & CEO
Inquiries:
Takashi Murakami, Corporate Officer, Finance & Investor Relations
Telephone:+81-3-6271-8958
Scheduled date to file semi-annual securities report:
August 13, 2024
Scheduled date to commence dividend payments:
September 12, 2024
Preparation of supplementary material on financial results:
Yes
Holding of financial results briefing:
Yes for Analysts

1. Consolidated Financial Results for the Six Months ended June 30, 2024
(From January 1, 2024, to June 30, 2024)*Figures are rounded down to the nearest million yen, except share and per share data*“%” indicates year-on-year changes from the previous corresponding period(1) Consolidated Operating Results (Cumulative)
Net sales

Operating profit

Recurring profit

Profit attributable toowners of parent

JPY MM%
JPY MM%
JPY MM%
JPY MM
Six months ended
June 30, 2024
3,205
42.5
940 136.7
945 128.1
701
June 30, 2023
2,249
0.7
397 (12.8)
414 (13.9)
283(Note) Comprehensive income: For the six months ended June 30, 2024: 714 million yen [148.8%]
For the six months ended June 30, 2023: 287 million yen [(10.8%)]

%

147.0
(11.3)

Basic earnings per share Diluted earnings per share
Six months ended
JPY
JPY
June 30, 2024
27.34
June 30, 2023
11.08
(Note) No statement is indicated above for the number of diluted EPS because there were no issuable shares.
(2) Consolidated Financial Position
Total assets
Net assets
Equity-to-asset ratio Net assets per share
As of
JPY MM
JPY MM%
JPY
June 30, 2024
6,414
5,345
83.2
208.03
December 31, 2023
5,934
4,845
81.5
188.67(Ref.) Equity amount: As of June 30, 2024: 5,339 million yen
As of December 31, 2023: 4,838 million yen
2. Cash Dividends
1st quarter
JPY－－

Annual dividends per share
2nd quarter3rd quarter
Year-end
JPY
JPY
JPY
4.00
－
9.00
7.00

Total
JPY
13.00

8.00

15.00

Fiscal year ended December 31, 2023
Fiscal year ending December 31, 2024
Fiscal year ending December 31, 2024－
(Forecast)(Note) Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated Financial Forecasts for the Fiscal Year ending December 31, 2024 (From January 1, 2024,
to December 31, 2024)* Figures are rounded down to the nearest million yen, except share and per share data
* “%” indicates year-on-year changes from the previous corresponding period
Profit attributable Basic earnings
OperatingRecurring
Net sales
to owners of
profitprofitper share
parent
JPY MM%

JPY MM%

JPY MM%

JPY MM

%

JPY

1,097

3.6

42.79

Fiscal year ending
5,782
11.4
1,574
5.2
1,591
4.2
December 31, 2024
(Note) Revisions to the financial forecasts most recently announced: None

*Notes:(1) Significant changes in the scope of consolidation during the period: None
Newly included companies: None, Newly excluded companies: None
(2) Adoption of accounting treatment specific to the preparation of semi-annual consolidated financial
statements: None
(3) Changes in Accounting Policies, Changes in Accounting Estimates, and Restatement(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None(ii) Changes in accounting policies due to other reasons: None(iii) Changes in accounting estimates: None(iv) Restatement: None
(4) Number of issued shares (Common Shares)
As of June 30, 2024
Total number of issued shares at the endof the period (including treasury shares)
Number of treasury shares at the end of
the period

As of December 31, 2023

26,608,800

26,608,800

943,933

962,288

Six months ended
June 30, 2024

Six months ended
June 30, 2023

Average number of shares outstanding
during the period (cumulative from the25,654,807
25,628,570
beginning of the fiscal year)(Note) The number of treasury shares at the end of the period includes our shares held by Custody Bank ofJapan, Ltd. (Trust Account E) (146,900 shares for H1FY2024, 154,400 shares for FY2023). Our shares heldby Custody Bank of Japan, Ltd. (Trust Account) are included in the treasury share deducted in thecalculation of the average number of shares during the period (150,877 shares for H1FY2024, 159,065
shares for H1FY2023).
* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an
audit firm.
* Proper use of earnings forecasts, and other special matters:
The performance forecast described in this report are based on information that is available to the Group, as well as
certain assumptions and estimates that are deemed to be reasonable, and we make no assurance that suchdescriptions prove to be correct. Actual figures may significantly differ due to various factors.

FINDEX Inc. (TSE 3649)
Financial Results for H1FY2024

Attached Material
Index
1. Qualitative Information on Interim Consolidated Financial Results…………………………………….
(1) Explanation on Operating Results………………………………………………………………….….

22(2) Explanation on the Financial Position …………………..…………………………………………….
(3) Explanation on Consolidated Financial Forecasts and Other Forward-looking Statements…………..

4
4

2. Interim Consolidated Financial Statements and Significant Notes Thereto……………………………..
(1) Interim Consolidated Balance Sheet ………………………………………………………………..

55(2) Interim Consolidated Statements of Income and Comprehensive Income ………………………….
Interim Consolidated Statement of Income, Cumulative……………………………………………

6
6

Interim Consolidated Statement of Comprehensive Income, Cumulative ………………………….
(3) Interim Consolidated Statement of Cash Flows……………………………………………………..

78(4) Notes to the Interim Consolidated Financial Statements…………………………..………………...
Notes on Segment Information etc ………………………………………………………………...…..

9
9

Notes on Significant Change in Equity Capital ……………………………………………………….
Notes on Going Concern Assumption.………………………………………………………………...

9
9Additional Information..……………………………………………………………………………….

9

3. Supplementary Information ………………………………………………………………………………. 10

1

FINDEX Inc. (TSE 3649)
Financial Results for H1FY2024

1. Qualitative Information on Interim Consolidated Financial Results(1) Explanation on Operating Results
The Group is dedicated to realizing its corporate philosophy of “Enriching society through technologies andcreation” by developing and providing products and services centered around solutions that promote
digitalization in medical software, medical equipment, and administrative organization. The Group is committed
to fostering research and development that encourages “the joy of creation” based on “new ideas and technology
exploration” and providing products that “exceed customer expectations and contribute to the development ofsociety” as its fundamental business policy.
The consolidated financial results for the six months ended June 30, 2024 are as follows.
(JPY in thousands)

Net sales
Operating profit
Recurring profit
Profit attributable toowners of the parent

Six months
ended June 30,2023
2,249,242
397,300
414,372

Six months
ended June30, 2024
3,205,521
940,372
945,376

283,881

701,324

Change(amount)

Change (%)

Progress rate(%)

956,279
543,072
531,00442.5%
136.7%
128.1%

55.4%
59.7%
59.4%

417,443147.0%

63.9%

In the first six months of the fiscal year ending December 31, 2024 (January 1, 2024 to June 30, 2024),
consolidated net sales were ¥3,205,521 thousand (+42.5% YoY), operating profit was ¥940,372 thousand(+136.7%), recurring profit was ¥945,376 thousand (+128.1%), and profit attributable to owners of the parent
was ¥701,324 thousand (+147.0%). The progress rate against the full-year performance forecast is 55.4% for net
sales, 59.7% for operating profit, 59.4% for recurring profit, and 63.9% for profit attributable to owners of theparent. The business environment has been generally favorable, and the Group’s performance is progressing asplanned towards achieving the full-year forecast. The Medical Business performed exceptionally well, leading
to record-high sales and profits in the first six months of the current fiscal year.
Consolidated results by segment for the first six months of the current fiscal year are as follows.
≪Medical Business≫(JPY in thousands)

Net sales
Operating profit

Six months ended
June 30, 2023
2,152,769
469,075

Six months ended
June 30, 2024
3,038,515
976,309

Change (amount)885,746507,233

Change (%)
41.1%
108.1%

Mainstay products in the Medical Business segment include the data management software Claio, the progressnote system C-Note, and the document management software DocuMaker. In addition to traditional on-premise
products, there has been an expansion in the cloud-based services. In May 2024, we launched DocuMaker
Cloud, a cloud-based document management, targeting small medical institutions and clinics.
Fitting Cloud Inc., a subsidiary specializing in cloud solutions and medical AI technology, released a solution
named "CocktailAI" aimed at streamlining physician tasks using generated AI. Additionally, the product was
showcased at the Japan Association for Medical Informatics Spring Conference, receiving high praise fromnumerous medical institutions.
In the first six months of the current fiscal year, 30 hospitals and 64 clinics newly installed, added on, or
updated our systems. The maintenance and consulting service also performed well. As a result, consolidated net
sales in this segment for the first six months were ¥3,038,515 thousand (+41.1% YoY) and operating profit was¥976,309 thousand (+108.1%). Despite the rise in personnel expenses due to salary increases and an increase instaff, we were able to absorb the increased costs through the sales growth effects contributed by large-scale
projects.

2

FINDEX Inc. (TSE 3649)
Financial Results for H1FY2024≪Public Sector Business≫(JPY in thousands)

Net sales
Operating profit or loss

Six months ended
June 30, 2023
57,018(11,458)

Six months ended
June 30, 2024
143,967
48,942

Change (amount)
86,94860,400Change (%)
152.5%-

Mainstay product in the Public Sector Business segment is DocuMaker Office, an archive management anddigital approval system, to support digitalization in public sector organizations.
In the first six months of the current fiscal year, 11 packaged solutions for local governments, and 4 packaged
solutions for hospitals have been installed. As a result, net sales in this segment were ¥143,967 thousand(+152.5% YoY) and operating profit was ¥48,942 thousand (versus the year-earlier operating loss of ¥11,458
thousand). With the increase in the number of users, monthly usage fees has remained stable, resulting inincreased sales and profit. For the packaged solutions provided to local governments, the successful
implementations at a prefectural office and other institutions have been favorable. There have led to theacquisition of one new project and an additional implementation for large-scale local governments during thisperiod. Additionally, for the packaged solutions specialized in back-office operations for medical institutions,
we are expanding our sales efforts targeting large and medium-sized hospitals that are currently using our
medical solutions.
In this segment, an increase in profits is anticipated through the accumulation of monthly usage fees as thenumber of existing users continues to grow. The number of cancellations since the launch of the service remains
at zero, and the establishment of a solid customer base has progressed steadily.
≪Health Tech Business≫(JPY in thousands)

Net sales
Operating loss

Six months ended
June 30, 2023
39,453(60,316)Six months ended
June 30, 2024
23,038(84,879)

Change (amount)(16,415)(24,562)

Change (%)(41.6%)-

Mainstay products in the Health Tech Business segment are the gaze analyzing perimeter GAP*1 and GAPscreener*2.
GAP is an affordable, groundbreaking wearable device that enhances availability by measuring a patient’svisual field with a completely different approach to that of conventional examination methods. It can also
contribute to the early detection of retinal diseases, such as glaucoma and other conditions that lack obvious
symptoms in the early stages. Unlike a conventional visual field examination, the product does not require theuse of a dark room, thus shortening the examination time and alleviating the burden on the patient. Moreover, bypromoting the use of the GAP at facilities that conduct medical exams and health checkups, early-stage retinal
disease patient data can be shared with R&D centers in Japan and overseas with the potential for it to contributeto the innovation of technology and solutions in numerous fields, including pharmaceuticals and life insurance.
In the six months of the current fiscal year, net sales in this segment were ¥23,038 thousand (-41.6% YoY).
We recorded an operating loss of ¥84,879 thousand, versus the year-earlier operating loss of ¥60,316 thousand.
Revenue and profit decreased year on year due to the reduction in the number of product shipments compared tothe previous year and the rise in personnel expenses due to additional hiring and salary increases.
In the first six months of the current fiscal year, a total of 7 units of the product were sold domestically.
GAP is distributed to ophthalmologic hospitals and clinics nationwide through various medical equipment
distributors, and the GAP-screener is sold to health check-up facilities through our distributors. In May 2024, a
paper on the performance of this product was published in the scientific journal “Ophthalmology Glaucoma” by
the American Academy of Ophthalmology, reaffirming its usefulness and accuracy as a perimeter.
(Note 1) Gaze Analyzing Perimeter, GAP (Notification No. of medical device manufacturing and sales
38B2X10003000002)(Note 2) Gaze Analyzing Perimeter, GAP-screener (Notification No. of medical device manufacturing and sales
38B2X10003000003)
3

FINDEX Inc. (TSE 3649)
Financial Results for H1FY2024(2) Explanation on the Financial Position
Status of Assets, Liabilities, and Net assets

AssetsLiabilities
Net Assets

As of December 31, 2023
5,934,285
1,088,925
4,845,360

As of June 30, 2024
6,414,161
1,068,854
5,345,307(JPY in thousands)
Change in Amount
479,876(20,070)499,946

Total assets at the end of the first six months of the current fiscal year amounted to ¥6,414,161 thousand, anincrease of ¥479,876 thousand from the end of the previous fiscal year. This was mainly due to an increase of¥461,735 thousand in current assets, primarily owing to an increase of ¥1,742,297 thousand in cash and deposits,
offset by a decrease of ¥1,188,681 thousand in notes and accounts receivable–trade, and contract assets.
Liabilities amounted to ¥1,068,854 thousand, a decrease of ¥20,070 thousand from the end of the previous fiscal
year. This was primarily attributable to a decrease of ¥45,109 thousand in non-current liabilities, offset by anincrease of ¥25,038 thousand in current liabilities.
Net assets amounted to ¥5,345,307 thousand, an increase of ¥499,946 thousand from the end of the previous
fiscal year. This was mainly due to an increase in shareholders’ equity of ¥486,896 thousand by virtue of anincrease in retained earnings.
(3) Explanation on Consolidated Financial Forecasts and Other Forward-looking Statements
We have revised upward our consolidated earnings forecast for the first six months of the fiscal year ending
December 31, 2024 (January 1, 2024, to June 30, 2024), based on the performance progress during this period. For
more details, please refer to the "Notice Regarding the Revision of the Financial Forecast for the Second Quarter of
the Fiscal Year Ending December 31, 2024" announced on July 26, 2024. Please note that the full-year
consolidated earnings forecast remains unchanged from the beginning of the fiscal year.

4

FINDEX Inc. (TSE 3649)
Financial Results for H1FY2024

2.

Interim Consolidated Financial Statements and Significant Notes Thereto(1) Interim Consolidated Balance Sheet(JPY in thousands)
As of December 31, 2023

AssetsCurrent assets
Cash and deposits
Notes and accounts receivable - trade, andcontract assets
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Total current assets
Non-current assets
Property, plant and equipment
Intangible assets
Software
Other
Total intangible assets
Investments and other assets
Total non-current assets
Total assets
Liabilities
Current liabilities
Accounts payable - trade
Accounts payable - other
Income taxes payable
Other
Total current liabilities
Non-current liabilities
Provision for share awards
Other
Total non-current liabilities
Total liabilities
Net assets
Shareholders' equity
Share capital
Capital surplus
Retained earnings
Treasury shares
Total shareholders' equity
Accumulated other comprehensive income
Valuation difference on available-for-salesecurities
Total accumulated other comprehensive
incomeNon-controlling interests
Total net assets
Total liabilities and net assets

5

As of June 30, 2024

2,693,160

4,435,457

1,924,104

735,423

216,844
3,967
118,376
50,502
5,006,955

123,877
1,751
116,589
55,5905,468,690

89,25589,423290,050344
290,394
547,680
927,330
5,934,285

295,691344
296,035
560,011945,471
6,414,161

39,37999,701
331,241
302,524
772,846

11,03890,896306,810389,140
797,885

233,125
82,952
316,078
1,088,925

229,219
41,749270,968
1,068,854

254,259
224,259
5,157,662(791,956)
4,844,223

254,259
227,2225,626,778(777,139)
5,331,120(5,386)

7,957(5,386)

7,957

6,522
4,845,360
5,934,285

6,228
5,345,307
6,414,161

FINDEX Inc. (TSE 3649)
Financial Results for H1FY2024(2) Interim Consolidated Statements of Income and Comprehensive Income(Interim Consolidated Statement of Income, Cumulative)(JPY in Thousands)
Six months ended
June 30, 2023
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating profit
Non-operating income
Interest income
Foreign exchange gains
Subsidy income
Royalty income
Other
Total non-operating income
Recurring profit
Extraordinary income
Insurance claim income
Total extraordinary income
Extraordinary losses
Compensation for damage
Total extraordinary losses
Profit before income taxes
Income taxes - current
Income taxes - deferred
Total income taxes
ProfitProfit (loss) attributable to non-controllinginterests
Profit attributable to owners of parent

6

Six months ended
June 30, 2024

2,249,242
968,830
1,280,411
883,111397,300

3,205,521
1,282,344
1,923,176
982,804
940,37234
12,280
2,814
1,660
281
17,071
414,372

39
－
3,114
1,660
189
5,003
945,376

19,00019,000－－22,00022,000411,372
118,263
6,016
124,279
287,092－－
945,376
240,2374,108
244,345
701,030

3,210

(293)

283,881

701,324

FINDEX Inc. (TSE 3649)
Financial Results for H1FY2024(Interim Consolidated Statement of Comprehensive Income, Cumulative）(JPY in Thousands)
Six months ended
June 30, 2023
ProfitOther comprehensive income
Valuation difference on available-for-salesecurities
Total other comprehensive income
Comprehensive income
Comprehensive income attributable toComprehensive income attributable to ownersof parent
Comprehensive income attributable to noncontrolling interests

7

Six months ended
June 30, 2024

287,092

701,030－

13,344－
287,092

13,344
714,374

283,881714,668

3,210

(293)

FINDEX Inc. (TSE 3649)
Financial Results for H1FY2024(3) Interim Consolidated Statement of Cash Flows(JPY in Thousands)
Six months ended
June 30, 2023
Cash flows from operating activities
Profit before income taxes
Depreciation
Amortization of software
Share-based payment expenses
Increase (decrease) in provision for shareawardsInterest and dividend income
Foreign exchange losses (gains)
Subsidy income
Insurance claim income
Loss on compensation for damage
Decrease (increase) in trade receivables
Decrease (increase) in inventories
Decrease (increase) in prepaid expenses
Decrease (increase) in accounts receivable other
Increase (decrease) in trade payables
Increase (decrease) in accounts payable - other
Increase (decrease) in accrued expenses
Increase (decrease) in accrued consumption
taxes
Other, net
SubtotalInterest and dividends received
Proceeds from insurance income
Compensation paid for damage
Income taxes paid
Net cash provided by (used in) operating
activities
Cash flows from investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of property, plant and equipment
Purchase of intangible assets
Payments of leasehold deposits
Proceeds from refund of leasehold deposits
Other, net
Net cash provided by (used in) investing
activities
Cash flows from financing activities
Dividends paid
Net cash provided by (used in) financing
activities
Net increase (decrease) in cash and cash
equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period

8

Six months ended
June 30, 2024

411,372
22,157103,359631

945,376
19,382
122,349
2,817

958

1,879

(34)
(12,280)(2,814)(19,000)
22,000605,489
2,585(7,239)(39)－(3,114)－－
1,188,681
96,969(12,824)

7,850

6,032

(62,569)(49,140)(6,899)(28,341)(6,335)
9,425(3,454)(17,584)

29,9081,042,879
12
19,000(22,000)(211,581)

64,9632,389,638
16－－(263,987)

828,310

2,125,667(78,000)
78,000(23,715)(109,348)
(17)
9
(17)

(90,000)
90,000(19,088)(128,887)(2,654)91(936)(133,089)(151,476)(167,153)(231,893)(167,153)(231,893)

528,067

1,742,297

2,287,747
2,815,814

2,563,160
4,305,457

FINDEX Inc. (TSE 3649)
Financial Results for H1FY2024(4) Notes to the Interim Consolidated Financial Statements(Notes on Segment Information etc)
[Segment Information]
Sales and Profit or Loss by Reportable Segment
Six Months ended June 30, 2023 (From January 1, 2023, to June 30, 2023)(JPY in thousands)

MedicalBusiness

Reportable segment
PublicHealth Tech
SectorBusiness
Business

Sub total

Reported amount for
consolidated financial
statements (Note)

Net sales
Sales for external
2,152,769
57,01839,4532,249,242
2,249,242
customers
Internal sales ortransfers between
segments
Total
2,152,769
57,01839,4532,249,242
2,249,242
Segment profit or loss
469,075(11,458)(60,316)
397,300
397,300(Note) Aggregated amount of segment profit or loss equals amount of operating profit reported for consolidated
financial statements.

Six Months ended June 30, 2024 (From January 1, 2024, to June 30, 2024)(JPY in thousands)

MedicalBusiness

Reportable segment
PublicHealth Tech
SectorBusiness
Business

Sub total

Reported amount for
consolidated financial
statements (Note)

Net sales
Sales for external
3,038,515
143,967
23,0383,205,521
3,205,521
customers
Internal sales ortransfers between
segments
Total
3,038,515
143,967
23,0383,205,521
3,205,521
Segment profit or loss
976,30948,942(84,879)
940,372
940,372(Note) Aggregated amount of segment profit or loss equals amount of operating profit reported for consolidated
financial statements.
(Notes on Significant Change in Equity Capital): N/A(Note on Going Concern Assumption): N/A【Additional Information】(Accounting Treatment for Employee Stock Ownership Plan, J-ESOP）
At the Board of Directors meeting held on October 29, 2015, the Company resolved to adopt an employee stock
ownership plan (referred to as J-ESOP) as an incentive plan to grant Company shares purchased from the market toemployees in order to more closely link the Company’s share price and earnings with employee compensation andto boost the motivation and morale of employees to improve the share price and earnings by sharing the economic
benefits with shareholders.
Accordingly, Trust & Custody Services Bank, Ltd. (trust account E) (now Custody Bank of Japan, Ltd. (trust
account E)) acquired 194,200 shares of the Company’s stock between November 13, 2015 and November 26, 2015.
Regarding accounting treatment for the J-ESOP, we have applied the gross method to record trust assets andliabilities as corporate assets and liabilities on the consolidated balance sheet in accordance with the Practical
Solution on Transactions of Delivering the Company's Own Stock to Employees etc. through Trusts (PITF No. 30,
March 26, 2015).
The treasury stock held by Custody Bank of Japan, Ltd. (trust account E) is shown as treasury shares in the net
assets section of the interm consolidated balance sheet. The amount recorded at the end of the previous fiscal year
was ¥119,108 thousand and the number of shares was 154,400. The amount recorded at the end of the first six
months of the current fiscal year was ¥113,323 thousand and the number of shares was 146,900.
9

FINDEX Inc. (TSE 3649)
Financial Results for H1FY2024

3.

Supplementary Information(1) Transition of Significant Financial Key Performance Indicators(JPY in thousands, except per share amounts)
Six months ended
Six months ended
Fiscal year ended
June 30, 2023
June 30, 2024
December 31, 2023
Net sales
2,249,242
3,205,521
5,191,735
Operating profit
Recurring profit

397,300
414,372

940,372
945,376

1,496,570
1,527,453

ProfitProfit (loss) attributable to owners of noncontrolling interests
Profit attributable to owners of parent

287,092

701,030

1,061,431

3,210

(293)

2,291

283,881

701,324

1,059,140

Comprehensive income
Net assets

287,092
4,177,296

714,374
5,345,307

1,056,045
4,845,360

Total assets
Net assets per share (yen)4,925,523
162.61

6,414,161
208.03

5,934,285
188.67

11.08

27.34

41.31

Basic earnings per share (yen)(2) Production, Order, Sales
1) Actual Result of Production for H1FY2024 (Cumulative Amount)
Business segment
Production (JPY in thousands)
Medical Business
780,398
Public Sector Business
Health Tech BusinessYoY (%)
106.2

45,51780,204

148.4
114.5

Total
906,120(Note) Figures above is calculated by total manufacturing cost for the current quarter.
2) Order Status for H1FY2024 (Cumulative Amount)
Order received
Business segment(JPY in thousands)
Medical Business
1,467,293
Public Sector Business
119,730
Health Tech Business
Total

YoY (%)
90.7
83.0

13,2001,600,223

81.4
90.0

108.5

Order backlog(JPY in thousands)
1,020,893

105,556

79.5
72.7

3,000
1,129,449

714.3
79.0

3) Sales Result for H1FY2024 (Cumulative Amount by Segments, Solutions, and Channels)
Segment, solution, channel
Sales amount (JPY in thousands)
Ratio (%)
Medical Business
Software1,698,014
53.0[of via distributors][344,433]
Hardware328,046
10.2[of via distributors][4,693]
Support779,48224.3[of via distributors][239,221]
Other
Public Sector Business
Software[of via distributors]
Hardware
Other
Health Tech Business

232,972

Total
10

YoY (%)YoY (%)
141.2
211.6
104.9

7.3

444.8

128,396[4,542]
7,668
7,902
23,038

4.0

225.2

0.2
0.3
0.7

58.4

3,205,521

100.0

142.5